Table 1.
Patient and tumor characteristics by age group (very elderly and younger status)
| |
All |
Very elderly ≥ 85 years |
Younger < 85 years |
p
value |
|---|---|---|---|---|
| (n = 81) | (n = 20) | (n = 61) | ||
| Age (years) |
|
|
|
|
| Median (range) |
80 (64–93) |
86 (85–93) |
78 (64–84) |
|
| Gender |
|
|
|
0.002* |
| Female |
17 |
9 |
8 |
|
| Male |
64 |
11 |
53 |
|
| Performance status (ECOG) |
|
|
|
0.44 |
| 0/1/2/3/4 |
55/24/2/0/0 |
14/6/0/0/0 |
41/18/2/0/0 |
|
| T stage |
|
|
|
0.57 |
| T1a/T1b/T2a |
42/21/18 |
9/7/4 |
33/14/14 |
|
| Histology |
|
|
|
0.62 |
| Adenocarcinoma |
35 |
11 |
24 |
|
| Squamous cell carcinoma |
27 |
5 |
22 |
|
| Unclassified NSCLC |
2 |
0 |
2 |
|
| Unproven |
17 |
4 |
13 |
|
| Tumor location |
|
|
|
0.64 |
| Central/Peripheral |
6/75 |
1/19 |
5/56 |
|
| Tumor opacity |
|
|
|
0.41 |
| Solid/GGO |
79/2 |
20/0 |
59/2 |
|
| Operability |
|
|
|
0.49 |
| Operable/Inoperable |
21/60 |
4/16 |
17/44 |
|
| Breath-hold |
|
|
|
0.02* |
| Yes/No |
50/31 |
8/12 |
42/19 |
|
| Total dose |
|
|
|
0.49 |
| 48 Gy/60 Gy |
60/21 |
16/4 |
44/17 |
|
| CTV (cc) |
|
|
|
0.92 |
| Mean ± SD (range) |
19.5 ± 18.5 (1.1–91) |
19.1 ± 19.3 (2.5–68) |
19.7 ± 18.4 (1.1–91) |
|
| PTV (cc) |
|
|
|
0.46 |
| Mean ± SD (range) |
69.1 ± 49.7 (9.3–224) |
76.3 ± 65.4 (14.3–224) |
66.8 ± 43.8 (9.3–205) |
|
| V20 (%) |
|
|
|
0.64 |
| Mean ± SD (range) |
5.9 ± 3.2 (1.5–16) |
6.2 ± 3.3 (1.6–14.9) |
5.8 ± 3.2 (1.5–16) |
|
| MLD (Gy) |
|
|
|
0.30 |
| Mean ± SD (range) | 3.9 ± 1.6 (1.2–9.2) | 4.2 ± 1.5 (1.6–7.6) |
3.8 ± 1.6 (1.2–9.2) |
Abbreviations: ECOG Eastern Cooperative Oncology Group, NSCLC non-small cell lung cancer, GGO ground-glass opacity, CTV clinical target volumes, PTV planning target volumes, V20 volumes of normal lung tissue exposed to ≥ 20 Gy, MLD mean lung doses.